Avon shareholders to vote on parabens
This article was originally published in The Rose Sheet
Executive Summary
Shareholders to vote on resolution requiring direct-seller to conduct study on the feasibility of removing parabens from products at annual meeting May 1. Resolution is sponsored by investment firm Domini Social Investments and advocacy group Breast Cancer Action. In proxy statement filed with Securities and Exchange Commission March 27, Avon advises shareholders to oppose the resolution, noting "parabens are recognized as safe by The World Health Organization and the Cosmetic Ingredient Review Expert Panel. Advocacy group argues parabens are linked to breast cancer. Group is targeting Avon because of the direct-seller's association with efforts to raise money to fight the disease. Avon has at least 82 products containing parabens...
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.